The FDA has given Laminate Medical Technologies investigational device exemption approval to conduct a 13-site, 129-patient trial of the VasQ implanted blood vessel external support device, which is intended for patients who need arteriovenous fistulas for dialysis. The trial will assess the primary patency rate at 6 months after the procedure, and patients will be followed as long as two years.
Laminate Medical's fistula support device gets IDE from FDA
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.